HealthWhy Lilly and Novo are betting on amylin for the next wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing amylin drugs as another biological mechanism for treating obesity and diabetes, seeking to drive a new generation of therapies beyond GLP-1 medicines.
C
CNBC★★☆☆☆2026-10-02 15:20Original
Why Lilly and Novo are betting on amylin for the next wave of obesity drugs after GLP-1s
Health